Genmab — Maj 2020

[GMAB]

Conclusions:
SC epcoritamab continues to demonstrate a favorable safety profile across all doses with no ≥Gr 3 CRS and no DLTs. Dose escalation data show improved efficacy as doses reach above the modeled predicted exposure threshold, inducing CRs in heavily pretreated DLBCL pts. All pts achieving CRs remain in remission. Clinical trial information: NCT03625037.

Anti-tumor activity in R/R B-NHL.
DLBCL/HGBCL ≥6 mg (n=12) FL ≥0.76 mg (n=7)
Evaluable pts 9 6
ORR, n(%) CR
PR 5 (56%) 4 (44%)
1 (11%)

[E_L]

https://meetinglibrary.asco.org/record/186016/abstract

[Sukkeralf]

Okay looks good - and data will be further updated at the ASCO meeting

[E_L]

no ≥Gr 3 CRS and no DLTs ; i guess that is the most important for now?

[E_L]

"Treatment is ongoing in 13 pts " from 41 does not seem much? or should i not read anyting into that?

[E_L]

then again, very ill patients with 3 to 5 prior lines of treatment.

[peter12]

Its dose escalation, so I guess not all are evaluated ? 44% CR sounds impressing

[gentogen]

For a dose escalation study this is crazy good

[gentogen]

the overall response rate (ORR) after induction treatment with DPd was 100%. ORR on day 100 post ASCT was 100%, 65% achieved ≥CR, and 81% achieved ≥VGPR. There was no treatment related mortality on day 100.

[transalp]

Go morgen.. der er stadig meget godt i vente..

[bibob]

God morgen. :-). Ja, og solen skinner

[Sukkeralf]

Teclistamab (JNJ-64007957)

[Sukkeralf]

https://meetinglibrary.asco.org/record/186864/abstract

[JKY_VH]

God morgen;-)

[Helge_LarsenPI-redaktør]

God morgen.

[GeorgeBest]

Amivantamab https://meetinglibrary.asco.org/record/184802/abstract

[Helge_LarsenPI-redaktør]

Tusinde tak GMAB, E L, Sukker og Gentogen.

[Helge_LarsenPI-redaktør]

Og GB.

[kkjoel]

Ritzau: "Biotekselskabet Genmab har fået løftet kursmålet til 1920 kr. fra 1750 kr. af finanshuset Bernst
ein.Anbefalingen er fortsat outperform, viser data fra Bloomberg News."

[kkjoel]

Og tusinde tak for acso links